The global nerve repair and regeneration market size was estimated at USD 7 billion in 2022 and is projected to hit around USD 15.47 billion by 2032 with a registered CAGR of 8.3% during the forecast period 2023 to 2032.
Access our Premium Real Time Data Intelligence Tool, Visit: Precedence Statistics
The leading firms' strong product pipelines and the increasing prevalence of neurological illnesses are what are propelling the market. Multiple technical advances that have improved the effectiveness of treating neurological illnesses are also anticipated to fuel market expansion.
The neurological operations of outpatient clinics were interfered with as a result of different government containment efforts during the pandemic. Social restriction measures put patients, such as people who had Parkinson's disease and dystonic patients receiving DBS, at a greater risk of chronic stress, and their motor and mental symptoms reportedly got worse. More options for effective neurological healthcare delivery are emerging as a result of rising investments in research in the area of nerve repair and regeneration. Over the course of the forecast period, ongoing research and development initiatives as well as private investments in the healthcare industry for improvements in surgery devices are anticipated to have a beneficial influence on market revenue growth.
Additionally, it is anticipated that market growth would trend upward as people's awareness of mental illnesses rises. In addition, rising Central Nervous System (CNS) disease instances and healthy living trends are two other important aspects anticipated to support market expansion in the future. However, during the course of the prediction period, the revenue growth of the worldwide nerve repair and regeneration market would be significantly constrained by the high cost of nerve repair and regeneration devices and unfavorable government policies.
Due to rising healthcare spending, especially in emerging nations, the market opportunity regarding nerve repair and regeneration is expanding. Market expansion is anticipated to be aided by the general rise in the knowledge of the use of nerve repair and regeneration technologies to treat neurological illnesses.
Report Scope of the Nerve Repair and Regeneration Market
|Market Size in 2023||USD 7.55 Billion|
|Market Size by 2032||USD 15.47 Billion|
|Growth Rate from 2023 to 2032||CAGR of 8.3%|
|Largest Market||North America|
|Fastest Growing Market||Asia Pacific|
|Forecast Period||2023 to 2032|
Key Market Drivers
Key Market Challenges
Key Market Opportunities
New markets, improvements in stem cell treatment for nerve repair and regeneration, and expanding neurology research projects
The growing advancement in technology
With a sales share of nearly 65.6% in 2022, the neurostimulation and neuromodulation devices market became the biggest segment. Deep brain stimulation, spinal cord stimulation, vagus nerve stimulation, sacral nerve stimulation, and gastric electric stimulation devices are further divided into this section. With a revenue share of more than 41%, the spinal cord stimulation devices category was the biggest sub-segment in 2022. The expansion of the category was attributed to the abundance of commercially accessible spinal cord goods and the variety of uses.
The market has been divided into two categories based on product: biomaterials and neurostimulation & neuromodulation devices. In the upcoming years, market growth is projected to be fueled by investments made by major corporations in the creation of more efficient gadgets. For instance, Boston Scientific's Precision Montage MRI Spinal Cord Stimulator System obtained FDA clearance in May 2016. According to the business, this technology reduces back discomfort by 70% more.
Due to technical improvements, a broad range of uses, government financing for innovations, and biocompatibility, the biomaterials category is expected to grow at the fastest CAGR between 2023 and 2032. Modern materials, such as biodegradable polymers, are anticipated to improve fracture healing and spinal stability while decreasing hospitalization.
In 2022, procedures using neurostimulation and neuromodulation accounted for more than 36% of total surgical revenue. The fastest CAGR over the anticipated years is anticipated for stem cell treatment. The market is expected to increase as a result of several government efforts and permissions to perform clinical studies of biomaterials. In the United States, there are now 570 clinics offering stem cell therapy, and this number is anticipated to expand, promoting segment growth.
The market is segmented based on surgery into direct nerve repair, also known as neurorrhaphy, nerve grafting, stem cell treatment, and neurostimulation and neuromodulation surgery. The market expansion is also projected to be boosted by the anticipated commercialization of the items in the upcoming years as a result of investments made by businesses and research institutions. For instance, Axonics Modulation Technologies' sacral nerve modulation device received CE mark clearance in the European Union in June 2016. After a further post-market clinical trial, the business intended to commercialize it.
Due to the availability of several products and technical breakthroughs for the treatment of chronic pain, neurostimulation and neuromodulation procedures are anticipated to continue their dominance during the forecast period. For instance, St. Jude introduced the Axium Neurostimulator System in the United States and authorized the implants for Dorsal Root Ganglion in April 2016. (DRG).
Nerve Repair and Regeneration Market Share, By Region, 2022 (%)
|Regions||Revenue Share in 2022 (%)|
Due to the region's favorable health insurance coverage environment and rising prevalence of neurological illnesses, North America held the majority of the market in 2022 with a share of over 33.6%. Due to the existence of significant market participants, technologically improved equipment is readily available in this area, which is a primary driver of its development. For instance, Reclaim DBS therapy was introduced by Medtronic plc in February 2016 to treat obsessive-compulsive disorder (OCD). Additionally, in May 2016, the FDA approved Boston Scientific's Precision Montage MRI-safe SCS for treating chronic pain.
Due to its expanding target market, growing patient awareness, encouraging government initiatives, the existence of unmet medical needs, and the introduction of cutting-edge technologies, the Asia Pacific region is anticipated to experience the fastest rate of growth in the region during the forecast period. China, India, Japan, Australia, and Singapore are the principal nations fostering regional development. The Australian Therapeutics Good Administration (TGA) approved clinical trials for the testing of a Parkinson's disease therapy technique based on human parthenogenetic stem cells (ISC-hpNSC) in December 2015. The market for stem cell treatment in the area was propelled by this permission.
Key Market Players
Segments covered in the report
PROCEED TO BUY :
ASK FOR SAMPLE
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client